|Title:||Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity|
|Abstract:||A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.|
|Inventor(s):||Lichtenberger; Lenard M. (Houston, TX)|
|Assignee:||THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)|
1. A method of reducing a GI toxic effect of a non-steroidal anti-inflammatory drug (NSAID) in a subject who ingests the NSAID, comprising administering the NSAID to the subject as an
NSAID-in-oil suspension that comprises lecithin oil and an NSAID, wherein the lecithin oil consists of soy lecithin components in sunflower oil and has about 33 to about 40 wt. % of phosphatidylcholine (PC), about 26 to about 31 wt. % triglycerides,
about 8 to about 13 wt. % free fatty acids, and about 5 to about 9 wt. % glycolipids, and wherein the NSAID is in an association complex with a phospholipid of the lecithin oil.
2. The method of claim 1, wherein said GI toxic effect is at least one effect selected from the group consisting of GI bleeding and GI tract ulceration.
3. The method of claim 1, wherein said NSAID is selected from the group consisting of aspirin, indomethacin, and ibuprofen.
4. The method of claim 3, wherein said NSAID is aspirin.
5. The method of claim 3, wherein said NSAID is ibuprofen.
6. The method of claim 1, wherein said subject suffers from at least one condition selected from the group consisting of tissue inflammation, tissue ulceration, pain, fever, cardiovascular disease, ovarian cancer, colon cancer, and Alzheimer's Disease.
7. The method of claim 6, wherein said subject suffers from cardiovascular disease.
8. The method of claim 3, wherein said NSAID is indomethacin.